BRPI0818865A2 - Anticorpos monoclonais contra proteína c ativada. - Google Patents

Anticorpos monoclonais contra proteína c ativada.

Info

Publication number
BRPI0818865A2
BRPI0818865A2 BRPI0818865A BRPI0818865A2 BR PI0818865 A2 BRPI0818865 A2 BR PI0818865A2 BR PI0818865 A BRPI0818865 A BR PI0818865A BR PI0818865 A2 BRPI0818865 A2 BR PI0818865A2
Authority
BR
Brazil
Prior art keywords
monoclonal antibodies
antibodies against
activated protein
against activated
protein
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
Jun Xu
Charles Esmon
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Publication of BRPI0818865A2 publication Critical patent/BRPI0818865A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
BRPI0818865 2007-10-26 2008-10-24 Anticorpos monoclonais contra proteína c ativada. BRPI0818865A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98309207P 2007-10-26 2007-10-26
PCT/US2008/081110 WO2009055669A2 (en) 2007-10-26 2008-10-24 Monoclonal antibodies against activated and unactivated protein c

Publications (1)

Publication Number Publication Date
BRPI0818865A2 true BRPI0818865A2 (pt) 2015-05-05

Family

ID=40289112

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818865 BRPI0818865A2 (pt) 2007-10-26 2008-10-24 Anticorpos monoclonais contra proteína c ativada.

Country Status (13)

Country Link
US (3) US8153766B2 (enExample)
EP (1) EP2205638B1 (enExample)
JP (3) JP2011500843A (enExample)
KR (2) KR101856210B1 (enExample)
CN (3) CN103232541A (enExample)
AU (1) AU2008316661B2 (enExample)
BR (1) BRPI0818865A2 (enExample)
CA (1) CA2703738C (enExample)
IL (2) IL205284A (enExample)
MX (1) MX2010004615A (enExample)
RU (2) RU2539729C2 (enExample)
WO (1) WO2009055669A2 (enExample)
ZA (1) ZA201105704B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2664473C2 (ru) * 2012-03-16 2018-08-17 Регенерон Фармасьютикалз, Инк. ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К pН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
EP2925351A4 (en) * 2012-11-29 2016-08-24 Bayer Healthcare Llc MONOCLONAL ANTIBODIES DIRECTED AGAINST ACTIVATED PROTEIN C (APC)
KR20150088853A (ko) * 2012-11-29 2015-08-03 바이엘 헬스케어 엘엘씨 활성화 단백질 c에 대한 인간화 모노클로날 항체 및 그의 용도
EP3047857A4 (en) * 2013-09-20 2017-08-09 Chugai Seiyaku Kabushiki Kaisha Treatment for hemorrhagic diseases by anti-protein-c antibody
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2015179435A1 (en) * 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
CN116284402A (zh) 2016-12-21 2023-06-23 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
KR102742528B1 (ko) 2017-06-20 2024-12-16 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
TW201906868A (zh) * 2017-07-07 2019-02-16 日商第一三共股份有限公司 抗蛋白ｃ抗體
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
JP7346389B2 (ja) * 2017-09-13 2023-09-19 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 異常な血小板レベルのマーカーとしてのプロアドレノメジュリン
US12319744B2 (en) 2018-09-06 2025-06-03 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)
AU2019360758B2 (en) * 2018-10-18 2024-08-08 Oklahoma Medical Research Foundation Biomarkers for a Systemic Lupus Erythematosus (SLE) disease activity immune index that characterizes disease activity
CN109897108B (zh) * 2019-03-11 2021-04-02 上海恒赛生物科技有限公司 抗人内皮蛋白c受体的羊驼单域抗体及应用
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用
KR20250000042A (ko) 2023-06-23 2025-01-02 충남대학교산학협력단 절단 반응성 펩타이드를 발현하는 키메라 t 세포 및 이를 포함하는 감염 질환 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
AU2001296483B2 (en) * 2000-10-02 2006-02-16 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein C and highly specific monoclonal antibody therefor
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same

Also Published As

Publication number Publication date
AU2008316661A1 (en) 2009-04-30
KR20100116166A (ko) 2010-10-29
JP6117741B2 (ja) 2017-04-19
RU2539729C2 (ru) 2015-01-27
KR20150092358A (ko) 2015-08-12
CA2703738C (en) 2018-02-27
ZA201105704B (en) 2014-05-28
KR101856210B1 (ko) 2018-05-09
MX2010004615A (es) 2010-07-06
US20120164150A1 (en) 2012-06-28
WO2009055669A3 (en) 2009-09-03
IL205284A0 (en) 2010-12-30
CA2703738A1 (en) 2009-04-30
IL205284A (en) 2014-06-30
CN105153308A (zh) 2015-12-16
EP2205638A2 (en) 2010-07-14
EP2205638B1 (en) 2017-03-01
IL220622A0 (en) 2012-08-30
US8153766B2 (en) 2012-04-10
US20090110683A1 (en) 2009-04-30
RU2010121148A (ru) 2011-12-10
JP2011500843A (ja) 2011-01-06
AU2008316661B2 (en) 2013-05-23
RU2012150953A (ru) 2014-06-10
WO2009055669A2 (en) 2009-04-30
JP2014237651A (ja) 2014-12-18
JP2013049694A (ja) 2013-03-14
CN101918453A (zh) 2010-12-15
US20150344588A1 (en) 2015-12-03
US9127072B2 (en) 2015-09-08
CN103232541A (zh) 2013-08-07

Similar Documents

Publication Publication Date Title
BRPI0818865A2 (pt) Anticorpos monoclonais contra proteína c ativada.
HUS2100038I1 (hu) Anti-CD20 antitest készítmények
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
BRPI0720218A2 (pt) Anticorpos monoclonais contra angptl3
CY2016030I2 (el) Αντισωματα εναντι της il-17
BRPI0811907A2 (pt) Anticorpos monoclonais contra claudina-18 para tratamento de câncer.
LTC2358756I2 (lt) Žmogaus antikūnai, pasižymintys dideliu giminingumu pcsk9
NO344963B1 (no) Humanisert antistoff
DK2066695T3 (da) Anti-myostatin-antistoffer
DK2225280T3 (da) Bivalente, bispecifikke antistoffer
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
BRPI0821405A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0821375A2 (pt) Anticorpos biespecíficos, bivalentes
DK2059533T3 (da) Multispecifikke antistoffer
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
DK2292663T3 (da) Antagonistiske human-let-specifikke, humane monoklonale antistoffer
BRPI0809677A2 (pt) Anticorpos anti-ige
BRPI0918947A2 (pt) proteína de fusão de anticorpo
BRPI0819165A2 (pt) Anticorpos anti-vegf
HRP20150176T1 (xx) Protutijela protiv miostatina
LT3421498T (lt) Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
NL1027975A1 (nl) Antilichamen tegen MAdCAM.
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2333 DE 22/09/2015

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]